RU2006136267A - Лечение тяжелой внебольничной пневмонии путем введения ингибитора пути тканевого фактора (tfpi) - Google Patents
Лечение тяжелой внебольничной пневмонии путем введения ингибитора пути тканевого фактора (tfpi) Download PDFInfo
- Publication number
- RU2006136267A RU2006136267A RU2006136267/14A RU2006136267A RU2006136267A RU 2006136267 A RU2006136267 A RU 2006136267A RU 2006136267/14 A RU2006136267/14 A RU 2006136267/14A RU 2006136267 A RU2006136267 A RU 2006136267A RU 2006136267 A RU2006136267 A RU 2006136267A
- Authority
- RU
- Russia
- Prior art keywords
- tfpi
- analog
- ala
- equivalent
- glycosylated
- Prior art date
Links
- 102100030951 Tissue factor pathway inhibitor Human genes 0.000 title claims 53
- 108010013555 lipoprotein-associated coagulation inhibitor Proteins 0.000 title claims 53
- 239000003112 inhibitor Substances 0.000 title claims 4
- 108010000499 Thromboplastin Proteins 0.000 title claims 2
- 102000002262 Thromboplastin Human genes 0.000 title claims 2
- 206010035664 Pneumonia Diseases 0.000 title 1
- 238000000034 method Methods 0.000 claims 42
- 238000001802 infusion Methods 0.000 claims 6
- 238000001990 intravenous administration Methods 0.000 claims 6
- 229940024606 amino acid Drugs 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 208000026425 severe pneumonia Diseases 0.000 claims 3
- 239000005557 antagonist Substances 0.000 claims 2
- 239000003242 anti bacterial agent Substances 0.000 claims 2
- 230000003115 biocidal effect Effects 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 claims 1
- 239000004475 Arginine Substances 0.000 claims 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 1
- 229940124073 Complement inhibitor Drugs 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 claims 1
- 229940124790 IL-6 inhibitor Drugs 0.000 claims 1
- 108010002352 Interleukin-1 Proteins 0.000 claims 1
- 102000004889 Interleukin-6 Human genes 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 claims 1
- 108010003541 Platelet Activating Factor Proteins 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102100040247 Tumor necrosis factor Human genes 0.000 claims 1
- 230000000844 anti-bacterial effect Effects 0.000 claims 1
- 230000002429 anti-coagulating effect Effects 0.000 claims 1
- -1 antibody Substances 0.000 claims 1
- 239000003146 anticoagulant agent Substances 0.000 claims 1
- 229940127219 anticoagulant drug Drugs 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 229960003121 arginine Drugs 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 229960003589 arginine hydrochloride Drugs 0.000 claims 1
- 102000052586 bactericidal permeability increasing protein Human genes 0.000 claims 1
- 108010032816 bactericidal permeability increasing protein Proteins 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 239000004074 complement inhibitor Substances 0.000 claims 1
- 239000002158 endotoxin Substances 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 229960002897 heparin Drugs 0.000 claims 1
- 229920000669 heparin Polymers 0.000 claims 1
- 229960001438 immunostimulant agent Drugs 0.000 claims 1
- 239000003022 immunostimulating agent Substances 0.000 claims 1
- 230000003308 immunostimulating effect Effects 0.000 claims 1
- 230000035699 permeability Effects 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims 1
- 239000001509 sodium citrate Substances 0.000 claims 1
- 102000003390 tumor necrosis factor Human genes 0.000 claims 1
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 claims 1
- 239000002451 tumor necrosis factor inhibitor Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55468104P | 2004-03-17 | 2004-03-17 | |
| US60/554681 | 2004-03-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2006136267A true RU2006136267A (ru) | 2008-04-27 |
Family
ID=35394617
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2006136267/14A RU2006136267A (ru) | 2004-03-17 | 2005-03-17 | Лечение тяжелой внебольничной пневмонии путем введения ингибитора пути тканевого фактора (tfpi) |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20080286279A1 (https=) |
| EP (1) | EP1729791A2 (https=) |
| JP (1) | JP2007532486A (https=) |
| KR (1) | KR20070007336A (https=) |
| CN (1) | CN101426520A (https=) |
| AU (1) | AU2005244249A1 (https=) |
| BR (1) | BRPI0508992A (https=) |
| CA (1) | CA2560103A1 (https=) |
| IL (1) | IL178115A0 (https=) |
| MX (1) | MXPA06010587A (https=) |
| NO (1) | NO20064674L (https=) |
| RU (1) | RU2006136267A (https=) |
| SG (1) | SG150552A1 (https=) |
| TN (1) | TNSN06295A1 (https=) |
| WO (1) | WO2005110059A2 (https=) |
| ZA (1) | ZA200608413B (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0916578D0 (en) * | 2009-09-22 | 2009-10-28 | Malmsten Nils M | Polypeptides and uses thereof |
| CN112587522B (zh) * | 2020-12-03 | 2022-11-25 | 中国海洋大学 | 替加色罗在制备用于预防或治疗冠状病毒感染的药物中的应用 |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4399216A (en) * | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4603106A (en) * | 1982-02-22 | 1986-07-29 | The Rockefeller University | Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay) |
| JPS5896026A (ja) * | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
| DE3219248A1 (de) * | 1982-05-21 | 1983-11-24 | Solco Basel AG, Birsfelden | Verfahren zur gewinnung zellatmungsfoerdernder wirkstoffe aus kaelberblut |
| EP0098110B1 (en) * | 1982-06-24 | 1989-10-18 | NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD | Long-acting composition |
| US4511502A (en) * | 1982-12-22 | 1985-04-16 | Genentech, Inc. | Purification and activity assurance of precipitated heterologous proteins |
| US4711845A (en) * | 1984-08-31 | 1987-12-08 | Cetus Corporation | Portable temperature-sensitive control cassette |
| US4569790A (en) * | 1984-03-28 | 1986-02-11 | Cetus Corporation | Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions |
| US4530787A (en) * | 1984-03-28 | 1985-07-23 | Cetus Corporation | Controlled oxidation of microbially produced cysteine-containing proteins |
| US4572798A (en) * | 1984-12-06 | 1986-02-25 | Cetus Corporation | Method for promoting disulfide bond formation in recombinant proteins |
| US4847201A (en) * | 1985-02-05 | 1989-07-11 | Cetus Corporation | DNA encoding for CSF-1 and accompanying recombinant systems |
| US4683195A (en) * | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4683202A (en) * | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4766106A (en) * | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US4748234A (en) * | 1985-06-26 | 1988-05-31 | Cetus Corporation | Process for recovering refractile bodies containing heterologous proteins from microbial hosts |
| JPS6345230A (ja) * | 1986-04-01 | 1988-02-26 | Central Glass Co Ltd | ブロモベンゾトリフルオリドの製造方法 |
| US5223427A (en) * | 1987-03-31 | 1993-06-29 | The Scripps Research Institute | Hybridomas producing monoclonal antibodies reactive with human tissue-factor glycoprotein heavy chain |
| US5110730A (en) * | 1987-03-31 | 1992-05-05 | The Scripps Research Institute | Human tissue factor related DNA segments |
| US4929700A (en) * | 1987-04-16 | 1990-05-29 | Cetus Corporation | Production of purified, biologically active, bacterially produced recombinant human CSF-1 |
| US5106833A (en) * | 1987-07-23 | 1992-04-21 | Washington University | Coagulation inhibitors |
| US5212091A (en) * | 1992-03-02 | 1993-05-18 | Monsanto Company | Method of producing tissue factor pathway inhibitor |
| US5276015A (en) * | 1992-03-18 | 1994-01-04 | Washington University | Method of inhibiting microvascular thrombosis |
| USRE36476E (en) * | 1992-03-18 | 1999-12-28 | Washington University | Method of inhibiting microvascular thrombosis |
| US6063764A (en) * | 1992-06-01 | 2000-05-16 | Washington University & Chiron Corp. | Method for using lipoprotein associated coagulation inhibitor to treat sepsis |
| US5589359A (en) * | 1994-08-05 | 1996-12-31 | Chiron Corporation | Chimeric proteins |
| JP3571378B2 (ja) * | 1994-09-30 | 2004-09-29 | 扶桑薬品工業株式会社 | 感染症診断用プローブ |
| US5914316A (en) * | 1994-12-16 | 1999-06-22 | Washington University | Method of inhibiting intimal hyperplasia |
| US5569644A (en) * | 1995-05-18 | 1996-10-29 | The Lubrizol Corporation | Additive combinations for lubricants and functional fluids |
| US5612363A (en) * | 1995-06-02 | 1997-03-18 | Berlex Laboratories, Inc. | N,N-di(aryl) cyclic urea derivatives as anti-coagulants |
| US6242414B1 (en) * | 1995-06-07 | 2001-06-05 | Chiron Corporation | Regulation of cytokine synthesis and release |
| US5885781A (en) * | 1995-06-07 | 1999-03-23 | Chiron Corporation | Regulation of cytokine synthesis and release |
| DE69635051T2 (de) * | 1995-06-07 | 2006-06-14 | Chiron Corp | Methode zur lösung, reinigung und rückfaltung von protein |
| US5888968A (en) * | 1995-06-07 | 1999-03-30 | Chiron Corporation | TFPI formulation |
| US5902582A (en) * | 1995-09-05 | 1999-05-11 | Chiron Corporation | Use of TFPI inhibitor for treatment of cancer |
| US6011136A (en) * | 1995-11-21 | 2000-01-04 | Novartis Ag | Cyclopeptolides |
| US5736364A (en) * | 1995-12-04 | 1998-04-07 | Genentech, Inc. | Factor viia inhibitors |
| ATE254472T1 (de) * | 1996-03-25 | 2003-12-15 | Chemo Sero Therapeut Res Inst | Hemmstoff für die gefässneubildung, der den gewebefaktor-inhibitor (tfpi) enthält |
| US5977057A (en) * | 1996-05-08 | 1999-11-02 | The University Of Vermont And State Agricultural College | Thrombosis prophylaxis for factor VLEIDEN carriers |
| US5981471A (en) * | 1997-02-06 | 1999-11-09 | Entremed, Inc. | Compositions and methods for inhibiting cellular proliferation |
| UA55448C2 (uk) * | 1997-04-28 | 2003-04-15 | Елі Ліллі Енд Компані | Стійка ліофілізована лікарська форма з активованим білком с (варіанти) та виріб, який її містить |
| HUP0001237A3 (en) * | 1997-10-20 | 2002-01-28 | Lilly Co Eli | Methods for treating vascular disorders |
| US6824997B1 (en) * | 1998-09-18 | 2004-11-30 | Binax, Inc. | Process and materials for the rapid detection of streptococcus pneumoniae employing purified antigen-specific antibodies |
| WO2000023101A1 (en) * | 1998-10-22 | 2000-04-27 | Eli Lilly And Company | Methods for treating sepsis |
| WO2000030677A1 (en) * | 1998-11-20 | 2000-06-02 | Eli Lilly And Company | Method of treating viral hemorrhagic fever |
| AU5062100A (en) * | 1999-06-14 | 2001-01-02 | Novo Nordisk A/S | Fviia/tf activity inhibiting compounds |
| US6294648B1 (en) * | 1999-07-20 | 2001-09-25 | Bayer Corporation | Protein having proteinase inhibitor activity |
| US6180607B1 (en) * | 1999-08-05 | 2001-01-30 | Christopher Davies | Protein having proteinase inhibitor activity |
| DE60031999T2 (de) * | 1999-10-04 | 2007-06-06 | Novartis Vaccines and Diagnostics, Inc., Emeryville | Stabilisierte flüssige polypeptid-haltige pharmazeutische zusammensetzungen |
| CA2400187A1 (en) * | 2000-02-11 | 2001-08-16 | Eli Lilly And Company | Protein c derivatives |
| DE10022092A1 (de) * | 2000-05-08 | 2001-11-15 | Aventis Behring Gmbh | Stabilisiertes Protein-Präparat und Verfahren zu seiner Herstellung |
| US7015194B2 (en) * | 2000-05-10 | 2006-03-21 | Novo Nordisk A/S | Pharmaceutical composition comprising factor VIIa and anti-TFPI |
| WO2002102325A2 (en) * | 2001-02-28 | 2002-12-27 | Griffin John H | Plasma glucosylceramide deficiency as risk factor for thrombosis and modulator of anticoagulant protein c |
| EP1383885A4 (en) * | 2001-04-04 | 2005-11-30 | American Diagnostica Inc | METHOD FOR PRODUCING A STABILIZED THROMBIN-ACTIVATED FIBRINOLYSE INHIBITOR (TAFI) AND METHOD FOR THE USE THEREOF |
| DE10132307A1 (de) * | 2001-07-06 | 2003-01-30 | Aventis Behring Gmbh | Arzneizubereitung zur Inhalation von Antithrombin bei entzündlichen Lungenerkrankungen und ARDS |
| EP1446140A4 (en) * | 2001-10-15 | 2007-03-07 | Novartis Vaccines & Diagnostic | TREATMENT OF HEAVY PNEUMONIA BY ADMINISTRATION OF TFPI (TISSUE FACTOR PATHWAY INHIBITOR) |
| US20020198138A1 (en) * | 2002-06-07 | 2002-12-26 | Macias William Louis | Combination therapy for the treatment of inflammatory and respiratory diseases |
-
2005
- 2005-03-17 SG SG200901403-6A patent/SG150552A1/en unknown
- 2005-03-17 CA CA002560103A patent/CA2560103A1/en not_active Abandoned
- 2005-03-17 AU AU2005244249A patent/AU2005244249A1/en not_active Abandoned
- 2005-03-17 BR BRPI0508992-1A patent/BRPI0508992A/pt not_active IP Right Cessation
- 2005-03-17 EP EP05777406A patent/EP1729791A2/en not_active Withdrawn
- 2005-03-17 CN CNA2005800144064A patent/CN101426520A/zh active Pending
- 2005-03-17 KR KR1020067021122A patent/KR20070007336A/ko not_active Withdrawn
- 2005-03-17 MX MXPA06010587A patent/MXPA06010587A/es not_active Application Discontinuation
- 2005-03-17 JP JP2007504145A patent/JP2007532486A/ja active Pending
- 2005-03-17 RU RU2006136267/14A patent/RU2006136267A/ru not_active Application Discontinuation
- 2005-03-17 WO PCT/US2005/009097 patent/WO2005110059A2/en not_active Ceased
- 2005-03-17 US US10/593,135 patent/US20080286279A1/en not_active Abandoned
-
2006
- 2006-09-14 IL IL178115A patent/IL178115A0/en unknown
- 2006-09-15 TN TNP2006000295A patent/TNSN06295A1/en unknown
- 2006-10-09 ZA ZA200608413A patent/ZA200608413B/en unknown
- 2006-10-16 NO NO20064674A patent/NO20064674L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005110059A3 (en) | 2009-04-09 |
| SG150552A1 (en) | 2009-03-30 |
| JP2007532486A (ja) | 2007-11-15 |
| IL178115A0 (en) | 2008-03-20 |
| CN101426520A (zh) | 2009-05-06 |
| WO2005110059A2 (en) | 2005-11-24 |
| CA2560103A1 (en) | 2005-11-24 |
| EP1729791A2 (en) | 2006-12-13 |
| BRPI0508992A (pt) | 2007-09-04 |
| MXPA06010587A (es) | 2007-03-29 |
| ZA200608413B (en) | 2008-06-25 |
| TNSN06295A1 (en) | 2007-12-03 |
| NO20064674L (no) | 2006-11-29 |
| AU2005244249A1 (en) | 2005-11-24 |
| US20080286279A1 (en) | 2008-11-20 |
| KR20070007336A (ko) | 2007-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20030012786A1 (en) | Use of anti-TNF antibodies as drugs in treating septic disorders of anemic patients | |
| Crosnier et al. | Randomised placebo-controlled trial of hepatitis B surface antigen vaccine in French haemodialysis units: II, haemodialysis patients | |
| JP2005506345A5 (https=) | ||
| US20100305048A1 (en) | Novel use of cytokine inhibitors | |
| TWI466679B (zh) | 環化胜肽之用途 | |
| JP2005515214A5 (https=) | ||
| CN1140414A (zh) | 抗tnf抗体作为治疗伴有白细胞介素-6血清水平升高的疾病的药物的应用 | |
| RU2006120950A (ru) | Антитело к cd40: препарат и способы | |
| SK42398A3 (en) | Application of r'-glu-trp-r''dipeptide for the treatment of neovascularization | |
| AU2011286486B2 (en) | Drug and method for the prophylaxis of HIV infection and for the prophylaxis and treatment of diseases caused by or associated with HIV, including aids | |
| KR20030034177A (ko) | 허혈성 질환 치료제 | |
| KR20190117579A (ko) | 화농성 한선염의 치료 | |
| US5543143A (en) | Method for activating macrophages/monocytes | |
| CN114746104A (zh) | 治疗由化疗或放疗引起的中性粒细胞减少症的方法 | |
| RU2006136267A (ru) | Лечение тяжелой внебольничной пневмонии путем введения ингибитора пути тканевого фактора (tfpi) | |
| AU756167B2 (en) | Application of TNF antagonists as medicaments for treating septic diseases | |
| RU2007142192A (ru) | Лечение тяжелой внебольничной пневмонии с помощью введения ингибитора пути тканевого фактора (tfpi) | |
| Palladino Jr et al. | Possible Relationships Between In Vivo Antitumour Activity and Toxicity of Tumour Necrosis Factor‐α | |
| RU2205026C1 (ru) | Лекарственное средство и способ лечения патологического синдрома, обусловленного нарушением кроветворения | |
| US20260028397A1 (en) | Methods of treating ankylosing spondylitis | |
| AU2022211867A1 (en) | Method of Treating Chronic Myeloid Leukemia Using Pegylated Interferon and Tyrosine Kinase Inhibitor | |
| JP2007532486A5 (https=) | ||
| Balkwill et al. | Effects of tumour necrosis factor on human tumour xenografts in nude mice | |
| CN114028544B (zh) | 一种动员淋巴瘤和骨髓瘤干细胞的药物组合物 | |
| TW518229B (en) | Prophylaxis and/or treatment agent for septicemia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA94 | Acknowledgement of application withdrawn (non-payment of fees) |
Effective date: 20101124 |